BioSpace News Archive

BeiGene announced that clinical results and updates from its diverse immuno-oncology portfolio will be presented at the European Society for Medical Oncology Immuno-Oncology Congress 2021 being held December 8-11, 2021.

Harbour BioMed is pleased to announce the appointment of Mr. Weihao Xu as Chief Strategy Officer, who will base in San Francisco.

Spago Nanomedical AB annouced that all patients have been recruited in the second dose group in the company’s ongoing clinical phase I study SPAGOPIX-01 with the tumor-selective contrast agent SpagoPix.

Tune Therapeutics, a biotechnology company pioneering the creation of epi-therapeutic medicines, launched with its powerful and precise genetic tuning platform, TEMPO.

Innate Pharma SA announced that it will present new data from the Phase 2 expansion cohort exploring the triplet combination of monalizumab, cetuximab and durvalumab, in first-line IO and chemo-naïve patients with recurrent or metastatic head and neck squamous cell cancer at the ESMO Immuno-oncology Congress 2021, being held virtually from December 8-11 2021.

Sixfold Bioscience, a company harnessing computation and advanced chemistry to design RNA therapeutic delivery systems, announced it has raised a total of $10.5 million USD in its seed funding round.

SQZ Biotechnologies Lead Cell Therapy Candidate Generated Monotherapy Clinical Response Correlated with Substantial CD8 T Cell Tumor Infiltration in HPV+ Solid Tumor at Highest Dose.

Veru Inc. today announced that fiscal 2021 full-year net revenues increased 44% to $61 million and gross profit increased 56% to $48 million, achieving new historical highs.

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that a poster presentation sharing new clinical data from the ongoing SRF617 Phase 1 trial will be presented at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021.

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the leading developer of spider silk-based fibers, announces today that it has begun production of the fourth generation of its specialized spider silk silkworms at its new production campus.